日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study

LOAd703(一种基于溶瘤病毒的免疫刺激基因疗法)联合化疗治疗不可切除或转移性胰腺癌(LOKON001):一项非随机、单中心、1/2期研究的第1组结果

Musher, Benjamin L; Rowinsky, Eric K; Smaglo, Brandon G; Abidi, Wasif; Othman, Mohamed; Patel, Kalpesh; Jawaid, Salmaan; Jing, James; Brisco, Amanda; Leen, Ann M; Wu, Mengfen; Sandin, Linda C; Wenthe, Jessica; Eriksson, Emma; Ullenhag, Gustav J; Grilley, Bambi; Leja-Jarblad, Justyna; Hilsenbeck, Susan G; Brenner, Malcolm K; Loskog, Angelica S I

Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial

嵌合抗原受体T细胞靶向CD19和GCC治疗转移性结直肠癌:一项非随机临床试验

Chen, Naifei; Pu, Chengfei; Zhao, Lingling; Li, Wei; Wang, Chang; Zhu, Ruihong; Liang, Tingting; Niu, Chao; Huang, Xi; Tang, Haiyang; Wang, Yizhuo; Yang, Hang; Jia, Beibei; Jiang, Xianyang; Han, Guiting; Wang, Wensheng; Chen, Dongqi; Wang, Yiming; Rowinsky, Eric K; Kennedy, Eugene; Lu, Victor X; Cui, Guozhen; Wu, Zhao; Xiao, Lei; Cui, Jiuwei

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

针对复发和/或难治性多发性骨髓瘤患者的蛋白质去泛素化酶抑制剂 VLX1570 的 1 期研究

Rowinsky, Eric K; Paner, Agne; Berdeja, Jesus G; Paba-Prada, Claudia; Venugopal, Parameswaran; Porkka, Kimmo; Gullbo, Joachim; Linder, Stig; Loskog, Angelica; Richardson, Paul G; Landgren, Ola

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

LXR/ApoE 激活限制癌症中的先天免疫抑制

Masoud F Tavazoie, Ilana Pollack, Raissa Tanqueco, Benjamin N Ostendorf, Bernardo S Reis, Foster C Gonsalves, Isabel Kurth, Celia Andreu-Agullo, Mark L Derbyshire, Jessica Posada, Shugaku Takeda, Kimia N Tafreshian, Eric Rowinsky, Michael Szarek, Roger J Waltzman, Elizabeth A Mcmillan, Connie Zhao, 

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

SL-401(一种靶向白细胞介素-3受体的生物制剂)对浆细胞样树突状细胞肿瘤的体内和体外敏感性

Angelot-Delettre, Fanny; Roggy, Anne; Frankel, Arthur E; Lamarthee, Baptiste; Seilles, Estelle; Biichle, Sabeha; Royer, Bernard; Deconinck, Eric; Rowinsky, Eric K; Brooks, Christopher; Bardet, Valerie; Benet, Blandine; Bennani, Hind; Benseddik, Zehaira; Debliquis, Agathe; Lusina, Daniel; Roussel, Mikael; Solly, Françoise; Ticchioni, Michel; Saas, Philippe; Garnache-Ottou, Francine

SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

SL-401 和 SL-501 是针对白细胞介素 3 受体的靶向治疗药物,可抑制晚期慢性粒细胞白血病中的白血病细胞和干细胞的生长

Olga Frolova, Juliana Benito, Chris Brooks, Rui-Yu Wang, Borys Korchin, Eric K Rowinsky, Jorge Cortes, Hagop Kantarjian, Michael Andreeff, Arthur E Frankel, Marina Konopleva

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy

KRAS基因3'非翻译区let-7 microRNA结合位点多态性可预测野生型KRAS转移性结直肠癌患者接受西妥昔单抗治疗的疗效

Zhang, W; Winder, T; Ning, Y; Pohl, A; Yang, D; Kahn, M; Lurje, G; LaBonte, M J; Wilson, P M; Gordon, M A; Hu-Lieskovan, S; Mauro, D J; Langer, C; Rowinsky, E K; Lenz, H-J

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

ramucirumab (IMC-1121B) 的 I 期药理学和生物学研究,ramucirumab 是一种靶向血管内皮生长因子受体-2 的全人源免疫球蛋白 G1 单克隆抗体

Spratlin Jennifer L, Cohen Roger B, Eadens Matthew, Gore Lia, Camidge D Ross, Diab Sami, Leong Stephen, O'Bryant Cindy, Chow Laura Q M, Serkova Natalie J, Meropol Neal J, Lewis Nancy L, Chiorean E Gabriela, Fox Floyd, Youssoufian Hagop, Rowinsky Eric K, Eckhardt S Gail

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

新型哺乳动物雷帕霉素靶点抑制剂 deforolimus (AP23573; MK-8669) 的 I 期临床试验,该药物每 2 周静脉注射 5 天,每天给药一次,用于治疗晚期恶性肿瘤患者

Monica M Mita, Alain C Mita, Quincy S Chu, Eric K Rowinsky, Gerald J Fetterly, Michelle Goldston, Amita Patnaik, Lesley Mathews, Alejandro D Ricart, Theresa Mays, Heather Knowles, Victor M Rivera, Jeff Kreisberg, Camille L Bedrosian, Anthony W Tolcher

Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine

顺铂与抗微管药物紫杉醇和长春新碱联合用药引起的序列依赖性细胞毒性效应

Rowinsky, E K; Citardi, M J; Noe, D A; Donehower, R C